Publication at First Faculty of Medicine, Second Faculty of Medicine |
2020
Abstract
We believe that the KAT6-LEUTX fusion is a very rare, yet recurrent fusion in AML, potentially more frequent in infants and among treatment-related AML, similar to KAT6-CREBBP (and KMT2Ar AML). Although acute myeloid leukemias in infants with other KAT6A fusions (KAT6A-CREBBP, KAT6A-EP300) are associated with a considerable chance of spontaneous remission, we observed an extremely aggressive course of the disease in a neonate with the biologically related KAT6A-LEUTX fusion.
This case demonstrates how complicated clinical decisions are in cAML, where we are unable to predict the course of the disease regardless of progress in molecular diagnostics and classification.